Paces of Costly Care: Rare Disease Drug Access in Canada

References

• Adams, V., ed. 2016 Metrics: What Counts in Global Health. Durham, NC: Duke University Press.
   Google Scholar
• Adams, V., M. Murphy, and A. E. Clarke 2009 Anticipation: technoscience, life, affect, temporality. Subjectivity 28(1):246–265. doi:10.1057/sub.2009.18.
   Google Scholar
• Alter, D., T. Stukel, A. Chong, and D. Henry 2011 Lesson from Canada’s universal health care: Socially disadvantaged patients use more health services, still have poorer health. Health Affairs 30(2):274–283. doi:10.1377/hlthaff.2009.0669.
   Web of Science ®Google Scholar
• Applbaum, K. 2009 Getting to yes: Corporate power and the creation of a psychopharmaceutical blockbuster. Culture, Medicine, and Psychiatry 33(2):185–215. doi:10.1007/s11013-009-9129-3.
   PubMed Web of Science ®Google Scholar
• Asbury, C. H. 1985 Orphan Drugs: Medical Versus Market Value. Lexington, MA: Lexington Books.
   Google Scholar
• Auyero, J. 2012 Patients of the State: The Politics of Waiting in Argentina. Durham, NC: Duke University Press.
   Google Scholar
• Becker, G. 1997 Disrupted Lives: How People Create Meaning in a Chaotic World. Berkeley, CA: University of California Press.
   Google Scholar
• Bellini, R. 2015 Specialty drug pricing: Worth risking payor wrath. Biotechnology Focus 18(1):13–14.
   Google Scholar
• Benchimol, E., T. To, A. Griffiths, L. Rabeneck, and A. Guttman 2011 Outcomes of pediatric inflammatory bowel disease: Socioeconomic status disparity in a universal health care system. The Journal of Pediatrics 158(6):960–967. doi:10.1016/j.jpeds.2010.11.039.
   PubMed Web of Science ®Google Scholar
• Biehl, J. 2011 Homo economicus and life markets. Medical Anthropology Quarterly 25(2):278–284.
   PubMed Web of Science ®Google Scholar
• Biehl, J. and A. Petryna 2011 Bodies of rights and therapeutic markets. Social Research 78(2):359–386.
   Web of Science ®Google Scholar
• Blackstock, C. 2012 Jordan’s principle: Canada’s broken promise to first nations children? Pediatrics & Child Health 17(7):368–370.
   PubMed Web of Science ®Google Scholar
• Briggs, C. L. and C. Mantini-Briggs 2016 Tell Me Why My Children Died: Rabies, Indigenous Knowledge, and Communicative Justice. Durham, NC: Duke University Press.
   Google Scholar
• Buchbinder, M. and S. Timmermans 2013 Affective economies and the politics of saving babies’ lives. Public Culture 26(1):101–126. doi:10.1215/08992363-2346268.
   Web of Science ®Google Scholar
• Collier, R. 2011 Bye, bye blockbusters, hello niche busters. Canadian Medical Association Journal 183(11):E697–698. doi:10.1503/cmaj.109-3874.
   Web of Science ®Google Scholar
• Coyle, D., M. Cheung, and G. Evans 2014 Opportunity cost of funding drugs for rare diseases. Medical Decision Making 34(8):1016–1029. doi:10.1177/0272989X14539731.
   PubMed Web of Science ®Google Scholar
• Daniels, N. and J. Sabin 2002 Setting Limits Fairly: Can We Learn to Share Scarce Resources? Oxford, UK: Oxford University Press.
   Google Scholar
• DelVecchio Good, M-J. 2001 The biotechnical embrace. Culture, Medicine and Psychiatry 25(4):395–410. doi:10.1023/A:1013097002487.
   PubMed Web of Science ®Google Scholar
• Epstein, S. 1998 Impure Science: AIDS, Activism, and the Politics of Knowledge. Oakland, CA: University of California Press.
   Google Scholar
• Fassin, D. 2011 Humanitarian Reason: A Moral History of the Present. Oakland, CA: University of California Press.
   Google Scholar
• Gibbon, S. and W. Aureliano 2018 Inclusion and exclusion in the globalization of genomics: The case of rare genetic disease in Brazil. Anthropology & Medicine 25(1):11–29. doi:10.1080/13648470.2017.1381230.
   PubMed Web of Science ®Google Scholar
• Hadjivasiliou, A. 2017 EvaluatePharma Orphan Drug Report. Evaluate Group 4th edition. London, UK: Evaluate Group. http://info.evaluategroup.com/rs/607-YGS-364/images/EPOD17.pdf
   Google Scholar
• Health Canada 2018 Canada’s Regulatory Approach to Drugs for Rare Diseases: Orphan Drugs. https://www.canada.ca/en/health-canada/services/licences-authorizations-registrations-drug-health-products/regulatory-approach-drugs-rare-diseases.html
   Google Scholar
• Huyard, C. 2009 How did uncommon disorders become ‘rare diseases’? History of a boundary object. Sociology of Health & Illness 31(4):463–477. doi:10.1111/j.1467-9566.2008.01143.x.
   PubMed Web of Science ®Google Scholar
• Kaufman, S. R. 2015 Ordinary Medicine: Extraordinary Treatments, Longer Lives, and Where to Draw the Line. Durham, NC: Duke University Press.
   Google Scholar
• Knight, K. R. 2015 Addicted. Pregnant. Poor. Durham, NC: Duke University Press.
   Google Scholar
• Lexchin, J. 2016 Private Profits versus Public Policy: The Pharmaceutical Industry and the Canadian State. Toronto, ON: University of Toronto Press.
   Google Scholar
• Mattingly, C. 2014 Moral Laboratories: Family Peril and the Struggle for a Good Life. Oakland, CA: University of California Press.
   Google Scholar
• Moreira, T. 2012 The Transformation of Contemporary Health Care: The Market, the Laboratory, and the Forum. New York, NY: Routledge.
   Google Scholar
• Novas, C. 2006 The political economy of hope: Patients’ organizations, science and biovalue. BioSocieties 1(3):289–305. doi:10.1017/S1745855206003024.
   Google Scholar
• Novas, C.. 2007 Patients, profits, and values: Myozyme as an exemplar of biosociality. In Biosocialities, Genetics, and the Social Sciences: Making Biologies and Identities. S. Gibbon and C. Novas, eds. Pp. 136–156. London: Routledge.
   Google Scholar
• Orphanet n.d. The portal for rare diseases and orphan drugs. www.orpha.net
   Google Scholar
• Petryna, A. 2011 Pharmaceuticals and the right to health: Reclaiming patients and the evidence base of new drugs. Anthropological Quarterly 84(2):305–329. doi:10.1353/anq.2011.0024.
   Web of Science ®Google Scholar
• PMPRB (Patented Medicines Prices Review Board) 2017 Meds Entry Watch 2015. Her Majesty the Queen in Right of Canada. Ottawa, ON: Government of Canada.
   Google Scholar
• Povinelli, E. 2011 Economies of Abandonment: Social Belonging and Endurance in Late Liberalism. Durham, NC: Duke University Press.
   Google Scholar
• Rabeharisoa, V., M. Callon, A. M. Filipe, J. A. Nunes, F. Paterson, and F. Vergnaud 2014 From ‘politics of numbers’ to ‘politics of singularisation’: Patients’ activism and engagement in research on rare diseases in France and Portugal. Biosocieties 9(2):194–217. doi:10.1057/biosoc.2014.4.
   Web of Science ®Google Scholar
• Sangaramoorthy, T. 2014 Treating AIDS: Politics of Difference, Paradox of Prevention. New Brunswick, NJ: Rutgers University Press.
   Google Scholar
• Standing Committee on Health 2018 Canada. Parliament. House of Commons. 1st sess., 42nd Parliament. Evidence Meeting No. 118. Barriers to Access Treatment and Drugs for Canadians Affected by Rare Diseases and Disorders, Ottawa, ON. http://www.ourcommons.ca/DocumentViewer/en/42-1/HESA/meeting-118/evidence
   Google Scholar
• Stevenson, L. 2014 Life beside Itself: Imagining Care in the Canadian Arctic. Berkeley, CA: University of California Press.
   Google Scholar
• Sunder Rajan, K. 2006 Biocapital: The Constitution of Postgenomic Life. Durham, NC: Duke University Press.
   Google Scholar
• Tallbear, K. 2013 Native American DNA: Tribal Belonging and the False Promise of Genetic Science. Minneapolis, MN: University of Minneapolis Press.
   Google Scholar
• Tambuyzer, E. 2010 Rare diseases, orphan drugs and their regulation: Questions and misconceptions. Nature Reviews Drug Discovery 9:921–929. doi:10.1038/nrd3275.
   PubMed Web of Science ®Google Scholar
• Ticktin, M. 2011 Casualties of Care: Immigration and the Politics of Humanitarianism in France. Oakland, CA: University of California Press.
   Google Scholar
• Waldby, C. and M. Cooper 2014 Clinical Labor: Tissue Donors and Research Subjects in the Global Bioeconomy. Durham, NC: Duke University Press.
   Google Scholar
• Winquist, E., D. Coyle, J. Clarke, G. Evans, C. Seager, W. Chan, and J. Martin 2014 Application of a policy framework for the public funding of drugs for rare diseases. Journal of General Internal Medicine 29(3):774–79. doi:10.1007/s11606-014-2885-y.
   Google Scholar